Pouchitis: What every gastroenterologist needs to know

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 12, 2013, Pages 1538-1549

  Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Ileal Pouch; Pouchitis; Restorative Proctocolectomy; Ulcerative Colitis

Indexed keywords

AMOXICILLIN; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; TACROLIMUS; TINIDAZOLE; TUMOR NECROSIS FACTOR INHIBITOR; VANCOMYCIN; VSL3;

ABDOMINAL RADIOGRAPHY; ANTIBIOTIC THERAPY; BIFIDOBACTERIUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; GASTROENTEROLOGIST; GASTROINTESTINAL ENDOSCOPY; GASTROJEJUNOSTOMY; HISTOLOGY; HUMAN; ILEITIS; INTESTINE FLORA; INTESTINE ISCHEMIA; LABORATORY TEST; LACTOBACILLUS; LACTOBACILLUS RHAMNOSUS; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PROCTOCOLECTOMY; RELAPSE; REVIEW; STREPTOCOCCUS SALIVARIUS;

CARD15; CARP; CASPASE RECRUITMENT DOMAIN FAMILY, MEMBER 15; CD; CDI; CHRONIC ANTIBIOTIC-REFRACTORY POUCHITIS; CLOSTRIDIUM DIFFICILE INFECTION; CMV; CROHN'S DISEASE; CYTOMEGALOVIRUS; FAMILIAL ADENOMATOUS POLYPOSIS; FAP; IBD; IL; ILEAL POUCH; ILEAL POUCH-ANAL ANASTOMOSIS; INFLAMMATORY BOWEL DISEASE; INTERLEUKIN; IPAA; IPS; IRRITABLE POUCH SYNDROME; NOD2; NONSTEROIDAL ANTI-INFLAMMATORY DRUG; NSAID; NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN CONTAINING 2; POUCHITIS; PRIMARY SCLEROSING CHOLANGITIS; PSC; RESTORATIVE PROCTOCOLECTOMY; TNF; TUMOR NECROSIS FACTOR; UC; ULCERATIVE COLITIS;

COLONIC POUCHES; HUMANS; POUCHITIS;

EID: 84887992627     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.03.033     Document Type: Review

References (131)

1. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
2. Targownik L.E., Singh H., Nugent Z., et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012, 107:1228-1235.
3. Penna C., Dozois R., Tremaine W., et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996, 38:234-239.
4. Fazio V.W., Ziv Y., Church J.M., et al. Ileal pouch-anal anastomosis complications and function in 1005 patients. Ann Surg 1995, 222:120-127.
5. Ferrante M., Declerck S., De Hertogh G., et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis 2008, 14:20-28.
6. Fleshner P., Ippoliti A., Dubinsky M., et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008, 6:561-568.
7. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
8. Tulchinsky H., Hawley P.R., Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003, 238:229-234.
9. Duffy M., O'Mahony L., Coffey J.C., et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum 2002, 45:384-388.
10. Nasmyth D.G., Godwin P.G., Dixon M.F., et al. Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship. Gastroenterology 1989, 96:817-824.
11. Komanduri S., Gillevet P.M., Sikaroodi M., et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol 2007, 5:352-360.
12. Sokol H., Lay C., Seksik P., et al. Analysis of bacterial bowel communities of IBD patients: what has it revealed?. Inflamm Bowel Dis 2008, 14:858-867.
13. Shen B.O., Jiang Z.D., Fazio V.W., et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008, 6:782-788.
14. Lim M., Sagar P., Finan P., et al. Dysbiosis and pouchitis. Br J Surg 2006, 93:1325-1334.
15. Scarpa M., Grillo A., Faggian D., et al. Relationship between mucosa-associated microbiota and inflammatory parameters in the ileal pouch after restorative proctocolectomy for ulcerative colitis. Surgery 2011, 150:56-67.
16. McLaughlin S.D., Walker A.W., Churcher C., et al. The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing. Ann Surg 2010, 252:90-98.
17. Tannock G.W., Lawley B., Munro K., et al. Comprehensive analysis of the bacterial content of stool from patients with chronic pouchitis, normal pouches, or familial adenomatous polyposis pouches. Inflamm Bowel Dis 2012, 18:925-934.
18. Li Y., Qian J., Queener E., et al. Risk factors and outcome of PCR-detected Clostridium difficile infection in ileal pouch patients. Inflamm Bowel Dis 2013, 19:397-403.
19. Shen B., Remzi F.H., Fazio V.W. Fulminant Clostridium difficile-associated pouchitis with a fatal outcome. Nat Rev Gastroenterol Hepatol 2009, 6:492-495.
20. Shen B. Campylobacter infection in patients with ileal pouches. Am J Gastroenterol 2010, 105:472-473.
21. Ingram S., McKinley J.M., Vasey F., et al. Are inflammatory bowel disease (IBD) and pouchitis a reactive enteropathy to group D streptococci (enterococci)?. Inflamm Bowel Dis 2009, 15:1609-1610.
22. Gosselink M.P., Schouten W.R., van Lieshout L.M., et al. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 2004, 47:1519-1525.
23. Muñoz-Juarez M., Pemberton J.H., Sandborn W.J., et al. Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as a refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum 1999, 42:117-120.
24. Moonka D., Furth E.E., MacDermott R.P., et al. Pouchitis associated with primary cytomegalovirus infection. Am J Gastroenterol 1998, 93:264-266.
25. Kroesen A.J., Leistenschneider P., Lehmann K., et al. Increased bacterial permeation in long-lasting ileoanal pouches. Inflamm Bowel Dis 2006, 12:736-744.
26. de Silva H.J., Jones M., Prince C., et al. Lymphocyte and macrophage subpopulations in pelvic ileal pouches. Gut 1991, 32:1160-1165.
27. Hirata I., Berrebi G., Austin L.L., et al. Immunohistological characterization of intraepithelial and lamina propria lymphocytes in control ileum and colon and in inflammatory bowel disease. Dig Dis Sci 1986, 31:593-603.
28. Stallmach A., Schäfer F., Hoffmann S., et al. Increased state of activation of CD4 positive T cells and elevated interferon gamma production in pouchitis. Gut 1998, 43:499-505.
29. Thomas P.D., Forbes A., Nicholls R.J., et al. Altered expression of the lymphocyte activation markers CD30 and CD27 in patients with pouchitis. Scand J Gastroenterol 2001, 36:258-264.
30. Goldberg P.A., Herbst F., Beckett C.G., et al. Leukocyte typing, cytokine expression and epithelial turn over in the ileal pouch in patients with ulcerative colitis and familial adenomatous polyposis. Gut 1996, 38:549-553.
31. Scarpa M., Grillo A., Pozza A., et al. TLR2 and TLR4 up-regulation and colonization of the ileal mucosa by Clostridiaceae spp. in chronic/relapsing pouchitis. J Surg Res 2011, 169:e145-e154.
32. Shepherd N.A., Healey C.J., Warren B.F., et al. Distribution of mucosal pathology and an assessment of colonic phenotype change in the pelvic ileal reservoir. Gut 1993, 34:101-105.
33. Coffey J.C., Rowan F., Burke J., et al. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol 2009, 104:1013-1023.
34. Tysk C., Riedesel H., Lindberg E., et al. Colonic glycoproteins in monozygote twins with inflammatory bowel disease. Gastroenterology 1991, 100:419-423.
35. Merrett M.N., Soper N., Mortensen N., et al. Intestinal permeability in the ileal pouch. Gut 1996, 39:226-230.
36. Toiyama Y., Araki T., Yoshiyama S., et al. The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg Today 2006, 36:287-290.
37. Heuschen G., Leowardi C., Hinz U., et al. Differential expression of Toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients. Int J Colorectal Dis 2007, 22:293-301.
38. Porter E.M., van Dam E., Valore E.V., et al. Broad-spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun 1997, 65:2396-2401.
39. Ayabe T., Satchell D.P., Wilson C.L., et al. Secretion of microbicidal α-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000, 1:113-118.
40. Salzman N.H., Ghosh D., Huttner K.M., et al. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 2003, 422:522-526.
41. Wehkamp J., Salzman N.H., Porter E., et al. Decreased Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005, 102:18129-18134.
42. Scarpa M., Grillo A., Scarpa M., et al. Innate immune environment in ileal pouch mucosa: α5 defensin up-regulation as predictor of chronic/relapsing pouchitis. J Gastrointest Surg 2012, 16:188-201.
43. Hirata N., Oshitani N., Kamata N., et al. Proliferation of immature plasma cells in pouchitis mucosa in patients with ulcerative colitis. Inflamm Bowel Dis 2008, 14:1084-1090.
44. Patel R.T., Bain I., Youngs D., et al. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum 1995, 38:831-837.
45. Schmidt C., Giese T., Ludwig B., et al. Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity. Int J Colorectal Dis 2006, 21:419-426.
46. Gionchetti P., Campieri M., Belluzzi A., et al. Mucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-α in pelvic ileal pouches. Dig Dis Sci 1994, 39:1525-1531.
47. Bulois P., Tremaine W.J., Maunoury V., et al. Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis 2000, 6:157-164.
48. Patel R.T., Pall A.A., Adu D., et al. Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995, 7:1037-1041.
49. Chaussade S., Denizot Y., Valleur P., et al. Presence of PAF-acether in stool of patients with pouch ileoanal anastomosis and pouchitis. Gastroenterology 1991, 100:1509-1514.
50. Gertner D.J., Rampton D.S., Madden M.V., et al. Increased leukotriene B4 release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis. Gut 1994, 35:1429-1432.
51. Romano M., Cuomo A., Tuccillo C., et al. Vascular endothelial growth factor and cyclooxygenase-2 are overexpressed in ileal pouch-anal anastomosis. Dis Colon Rectum 2007, 50:650-659.
52. Stucchi A.F., Shebani K.O., Leeman S.E., et al. A neurokinin 1 receptor antagonist reduces an ongoing ileal pouch inflammation and the response to a subsequent inflammatory stimulus. Am J Physiol Gastrointest Liver Physiol 2003, 285:G1259-G1267.
53. Stallmach A., Chan C.C., Ecker K.W., et al. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 2000, 47:415-422.
54. Ulisse S., Gionchetti P., D'Alò S., et al. Expression of cytokines, inducible nitric oxide synthase, matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001, 96:2691-2699.
55. Leal R.F., Coy C.S., Ayrizono M.L., et al. Differential expression of pro-inflammatory cytokines and a pro-apoptotic protein in pelvic ileal pouches for ulcerative colitis and familial adenomatous polyposis. Tech Coloproctol 2008, 12:33-38.
56. Carter M.J., Di Giovine F.S., Cox A., et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 2001, 121:805-811.
57. Meier C.B., Hegazi R.A., Aisenberg J., et al. Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor?. Inflamm Bowel Dis 2005, 11:965-971.
58. Tyler A.D., Milgrom R., Stempak J.M., et al. The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. Gut 2013, 62:1433-1439.
59. Lammers K.M., Ouburg S., Morré S.A., et al. Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. World J Gastroenterol 2005, 11:7323-7329.
60. Sehgal R., Berg A., Polinski J.I., et al. Genetic risk profiling and gene signature modeling to predict risk of complications after IPAA. Dis Colon Rectum 2012, 55:239-248.
61. Schmidt C.M., Lazenby A.J., Hendrickson R.J., et al. Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. Ann Surg 1998, 227:654-662.
62. Achkar J.P., Al-Haddad M., Lashner B., et al. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol 2005, 3:60-66.
63. White E., Melmed G.Y., Vasiliauskas E.A., et al. A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitis. Dis Colon Rectum 2010, 53:987-994.
64. Okon A., Dubinsky M., Vasiliauskas E.A., et al. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Am Surg 2005, 71:821-826.
65. Hata K., Watanabe T., Shinozaki M., et al. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol 2003, 38:1055-1058.
66. Lepistö A., Kärkkäinen P., Järvinen H.J. Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis. Inflamm Bowel Dis 2008, 14:775-779.
67. Shen B., Remzi F.H., Nutter B., et al. Association between immune-associated disorders and adverse outcomes of ileal pouch-anal anastomosis. Am J Gastroenterol 2009, 104:655-664.
68. Shen B., Fazio V.W., Remzi F.H., et al. Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2006, 4:81-89.
69. Shen B., Plesec T.P., Remer E., et al. Asymmetric endoscopic inflammation of the ileal pouch: a sign of ischemic pouchitis?. Inflamm Bowel Dis 2010, 16:836-846.
70. Fleshner P.R., Vasiliauskas E.A., Kam L.Y., et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001, 49:671-677.
71. Kuisma J., Järvinen H., Kahri A., et al. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol 2004, 39:544-548.
72. Navaneethan U., Venkatesh P.G., Kapoor S., et al. Elevated serum IgG4 is associated with chronic antibiotic-refractory pouchitis. J Gastrointest Surg 2011, 15:1556-1561.
73. Navaneethan U., Venkatesh P.G., Manilich E., et al. Prevalence and clinical implications of positive serum anti-microsomal antibodies in symptomatic patients with ileal pouches. J Gastrointest Surg 2011, 15:1577-1582.
74. Hoda K.M., Collins J.F., Knigge K.L., et al. Predictors of pouchitis after ileal pouch-anal anastomosis: a retrospective review. Dis Colon Rectum 2008, 51:554-560.
75. Fleshner P., Ippoliti A., Dubinsky M., et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2007, 5:952-958.
76. Shen B., Achkar J.P., Lashner B.A., et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 2001, 121:261-267.
77. Moskowitz R.L., Shepherd N.A., Nicholls R.J. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986, 1:167-174.
78. Sandborn W.J., Tremaine W.J., Batts K.P., et al. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 1994, 69:409-415.
79. Shen B., Sanmiguel C., Bennett A.E., et al. Irritable pouch syndrome is characterized by visceral hypersensitivity. Inflamm Bowel Dis 2011, 17:994-1002.
80. Elder K., Lopez R., Kiran R.P., et al. Endoscopic features associated with ileal pouch failure. Inflamm Bowel Dis 2013, 19:1202-1209.
81. Tang L., Cai H., Moore L., et al. Evaluation of endoscopic and imaging modalities in the diagnosis of structural disorders of the ileal pouch. Inflamm Bowel Dis 2010, 16:1526-1531.
82. Kariv R., Plesec T.P., Gaffney K., et al. Pyloric gland metaplasia and pouchitis in patients with ileal pouch-anal anastomoses. Aliment Pharmacol Ther 2010, 31:862-873.
83. Jiang W., Goldblum J.R., Lopez R., et al. Increased crypt apoptosis is a feature of autoimmune-associated chronic antibiotic refractory pouchitis. Dis Colon Rectum 2012, 55:549-557.
84. Navaneethan U., Bennett A.E., Venkatesh P.G., et al. Tissue infiltration of IgG4+ plasma cells in symptomatic patients with ileal pouch-anal anastomosis. J Crohns Colitis 2011, 5:570-576.
85. M'Koma A.E., Wise P.E., Schwartz D.A., et al. Prevalence and outcome of anemia after restorative proctocolectomy: a clinical literature review. Dis Colon Rectum 2009, 52:726-739.
86. Miller H.L., Farraye F.A., Coukos J., et al. Vitamin D deficiency and insufficiency are common in ulcerative colitis patients after ileal pouch-anal anastomosis. Inflamm Bowel Dis 2013, 19:E25-E26.
87. Khanna R., Wu X., Shen B. Low levels of vitamin D are common in patients with ileal pouches irrespective of pouch inflammation. J Crohns Colitis 2013, 7:525-533.
88. Shen B., Fazio V.W., Remzi F.H., et al. Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders. Dig Dis Sci 2007, 52:3321-3328.
89. McLaughlin S.D., Clark S.K., Shafi S., et al. Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis. Clin Gastroenterol Hepatol 2009, 7:545-548.
90. Parsi M.A., Shen B., Achkar J.P., et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004, 126:1280-1286.
91. Lim M., Gonsalves S., Thekkinkattil D., et al. The assessment of a rapid noninvasive immunochromatographic assay test for fecal lactoferrin in patients with suspected inflammation of the ileal pouch. Dis Colon Rectum 2008, 51:96-99.
92. Parsi M.A., Ellis J.J., Lashner B.A. Cost-effectiveness of quantitative fecal lactoferrin assay for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. J Clin Gastroenterol 2008, 42:799-805.
93. Johnson M.W., Maestranzi S., Duffy A.M., et al. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol 2008, 20:174-179.
94. Shen B., Achkar J.P., Lashner B.A., et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001, 7:301-305.
95. Wu X., Zhu H., Kiran R.P., et al. Excessive weight gain is associated with an increased risk for pouch failure in patents with restorative proctocolectomy. Gastroenterology 2013, 144(Suppl 1):S188-S189.
96. Lohmuller J.L., Pemberton J.H., Dozois R.R., et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990, 211:622-629.
97. Mowschenson P.M., Critchlow J.F., Peppercorn M.A. Ileoanal pouch operation: long-term outcome with or without diverting ileostomy. Arch Surg 2000, 135:463-465.
98. Hurst R.D., Chung T.P., Rubin M., et al. The implications of acute pouchitis on the long-term functional results after restorative proctocolectomy. Inflamm Bowel Dis 1998, 4:280-284.
99. Madiba T.E., Bartolo D.C. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J R Coll Surg Edinb 2001, 46:334-337.
100. McLaughlin S.D., Culkin A., Cole J., et al. Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis. J Crohns Colitis 2013, 7:460-466.
101. Gosselink M.P., Schouten W.R., van Lieshout L.M., et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004, 47:876-884.
102. Nicholls R.J. Review article: ulcerative colitis-surgical indications and treatment. Aliment Pharmacol Ther 2002, 16(Suppl 4):25-28.
103. Ha C.Y., Bauer J.J., Lazarev M., et al. Early institution of tinidazole may prevent pouchitis following ileal pouch anal anastomosis (IPAA) surgery in ulcerative colitis (UC) patients. Gastroenterology 2010, 138(Suppl):S-69.
104. Isaacs K.L., Sandler R.S., Abreu M., et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007, 13:1250-1255.
105. Madden M.V., McIntyre A.S., Nicholls R.J. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994, 39:1193-1196.
106. Holubar S.D., Cima R.R., Sandborn W.J., et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010, 6. CD001176.
107. McLaughlin S.D., Clark S.K., Bell A.J., et al. An open study of antibiotics for the treatment of pre-pouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis. Aliment Pharmacol Ther 2009, 29:69-74.
108. Shen B., Pardi D.S., Bennett A.E., et al. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis. Am J Gastroenterol 2009, 104:1468-1474.
109. Navaneethan U., Venkatesh P.G.K., Bennett A.E., et al. Impact of budesonide on liver function tests and gut inflammation in patients with primary sclerosing cholangitis and ileal pouch-anal anastomosis. J Crohns Colitis 2012, 6:536-542.
110. Gionchetti P., Rizzello F., Morselli C., et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007, 50:2075-2084.
111. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
112. Mimura T., Rizzello F., Helwig U., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
113. Shen B., Brzezinski A., Fazio V.W., et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005, 22:721-728.
114. McLaughlin S.D., Johnson M.W., Clark S.K., et al. VSL#3 for chronic pouchitis: experience in UK clinical practice. Gastroenterology 2008, 134(Suppl 1):A711.
115. Shen B., Remzi F.H., Lopez A.R., et al. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008, 8:26.
116. Shen B., Fazio V.W., Remzi F.H., et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007, 50:498-508.
117. Gionchetti P., Rizzello F., Venturi A., et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999, 13:713-718.
118. Abdelrazeq A.S., Kelly S.M., Lund J.N., et al. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 2005, 7:182-186.
119. Mimura T., Rizzello F., Helwig U., et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002, 16:909-917.
120. Gionchetti P., Rizzello F., Poggioli G., et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007, 25:1231-1236.
121. Barreiro-de Acosta M., García-Bosch O., Souto R., et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis 2012, 18:812-817.
122. Barreiro-de Acosta M., García-Bosch O., Gordillo J., et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012, 24:756-758.
123. Colombel J.F., Ricart E., Loftus E.V., et al. Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol 2003, 98:2239-2244.
124. Li Y., Lopez R., Queener E., et al. Adalimumab therapy in Crohn's disease of the ileal pouch. Inflamm Bowel Dis 2012, 18:2232-2239.
125. Shen B., Lian L., Kiran R.P., et al. Efficacy and safety of endoscopic treatment of ileal pouch strictures. Inflamm Bowel Dis 2011, 17:2527-2535.
126. Ananthakrishnan A.N., Issa M., Binion D.G. Clostridium difficile and inflammatory bowel disease. Med Clin North Am 2010, 94:135-153.
127. Gerding D.N., Muto C.A., Owens R.C. Treatment of Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S32-S42.
128. Pepin J., Alary M.E., Valiquette L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005, 40:1591-1597.
129. Zoetendal E.G., Rajilic-Stojanovic M., De Vos W.M. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008, 57:1605-1615.
130. Liu Z.X., Deroche T., Remzi F.H., et al. Transmural inflammation is not pathognomonic for Crohn's disease of the pouch. Surg Endosc 2011, 25:3509-3517.
131. Shen B., Remzi F.H., Lavery I.C., et al. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol 2008, 6:145-148.